EUnetHTA Covid-19 Response
To help in the development of a coordinated response to the Covid-19 pandemic, it is essential that researched, timely and reliable information can be made available to all stakeholders, whether healthcare professionals or members of the public. With this in mind,
EUnetHTA Open Call for Early Dialogue Requests
The EUnetHTA ED Secretariat is holding an Open Call to fill the slots available for EDs through May 31, 2021. EUnetHTA will aim to conduct 1 ED per month with a maximum 8 EDs during the EUnetHTA prolongation period. The Open
OTCA24 Final Assessment Report now available.
The final assessment report and related documentation is now available for Rapid Relative Effectiveness Assessment OTCA24 'The 24-hour blood pressure measurement device Mobil-O- Graph® with the built-in algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment'. Mobil-O-Graph® is
RCR01-RCRXX Covid-19 Rolling Collaborative Review – Project Plan now available
As part of its response to the Covid-19 pandemic, EUnetHTA is working to output 'Rolling Collaborative Reviews (RCR)'. The objective of such reviews is to provide decision-makers with a timely synthesis of available evidence on the comparative effectiveness of therapeutic
OTCA28 – ‘Lung cancer screening in risk groups’ – final project plan and related documents
The Final Project Plan and related documents for Other Technologies Collaborative Assessment 28 (OTCA28) 'Lung cancer screening in risk groups' are now available for access. Please follow the links: OTCA28 - Final Project Plan OTCA28 - Comments from External Experts
OTCA25 Final Project Plan and related documents now available
The Final Project Plan and comments from external experts are now available for the Other Technologies Collaborative Assessment 25 (OTCA25) 'Stereotactic Body Radiation Therapy (SBRT) for lung, prostate and liver cancer'. Please access at the following links: OTCA25 Final Project Plan OTCA25 Comments
EUnetHTA Early Dialogues – Status during EUnetHTA prolongation period
The current pandemic situation has put additional strain on European health systems and HTA bodies have not been immune to this impact. The unfortunate result of this has been the temporary suspension of EUnetHTA Early Dialogues (EDs). We are pleased to
RCR OT 01 – “Rapid collaborative review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic” – final assessment now available
EUnetHTA is pleased to announce that the "Rapid Collaborative Review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic" is now available. This is the first rapid review assessing health technologies for
OTCA21 ‘Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea’ Final Assessment now available
EUnetHTA is pleased to announce that the OTCA21 Final Assessment is now available for access. The assessed technology is Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea. The aim of this assessment was to evaluate effectiveness and safety of
PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options – Final assessment now available
This is the pharmaceutical Joint Assessment PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. In April 2020, the European Commission granted marketing authorisation for Fetcroja® (cefiderocol) for the